BioCryst Pharmaceuticals
BCRX
BCRX
73 hedge funds and large institutions have $217M invested in BioCryst Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
Holders
73
Holding in Top 10
2
Calls
$4.96M
Puts
$3.02M
Top Buyers
| 1 | +$42.5M | |
| 2 | +$19.2M | |
| 3 | +$11.9M | |
| 4 |
VM
VHCP Management
New York
|
+$8.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$8.27M |
Top Sellers
| 1 | -$2.85M | |
| 2 | -$1.62M | |
| 3 | -$1.29M | |
| 4 |
Barclays
London,
United Kingdom
|
-$1M |
| 5 |
Morgan Stanley
New York
|
-$760K |